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The monoclonal antibody 19-9 was originally raised
against a human colon carcinoma cell line, SW 116
(Koprowski et al., 1981). The antigen defined is a
carbohydrate determinant of a circulating antigen
designated CA19-9 (Del Villano et al., 1983). A
radioimmunoassay to detect CA19-9 in serum was
recently developed (Del Villano et al., 1983) and
elevated levels of CA19-9 have been found
association with a wide range of benign and
malignant conditions (Del Villano & Zurawski,
1983) including ovarian carcinomas (Ricolleau et
al., 1983).
To date CA125 has shown the most clinical
promise as a marker for ovarian tumours (Bast et
al., 1983; Canney et al., 1984). The present study
has investigated CA19-9 levels in the serum of
patients with known ovarian carcinoma in whom
CA125 levels were also recently measured. The
object was to test CA19-9 as a serum marker alone
and in comparison with CA125 to see if the pair of
antigens provided more information than each one
separately.
Sera of 55 patients with histologically proven
ovarian adenocarcinoma, known to have persisted
after laparotomy, or to have recurred after previous
treatment, were examined for CA19-9 levels.
The sampling procedure, treatment methods and
assessment of patients were as described in the first
part ofthe study (Canney et al., 1984).
CA19-9 was measured using a solid phase
sandwich radioimmunoassay (International CIS,
UK, Ltd., London). Sera were stored at -20°C
until assayed. The upper limit of normal was taken
as 33uml-1, a level exceeded by 1% of 260
presumed normal subjects (manufacturers
information).
CA125 was also measured using a commercially
available immunoradiometric assay (International
CIS, UK Ltd) as previously described (Canney et
al., 1984).
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The sensitivity of the assay (defined as no. true
+ve no. true +ve + no. false negative) for
ovarian adenocarcinomas is shown in Table I. The
overall sensitivity was 29% with a proportion of all
the histological types being positive. A further two
patients with granulosa cell tumours had CAI9-9
levels <33Uml-1. There was no correlation
between elevation of serum CA19-9 and bulk of
residual tumour, the antigen having been detected
as frequently in patients with minimal residual
disease (no lesion >2cm) as in patients with gross
bulk disease (any lesion > 10cm). (Table II).
Twelve patients whose initial CA19-9 level was
elevated had serial levels performed during the
course of their treatment. Changes in measured
serum antigen level versus clinical response are
shown in Figure 1. No patient who responded to
treatment had a rising CAl9-9 titre, and in all three
cases the antigen level was within the normal range
Table I Frequency of detection of an elevated serum
serum CA19-9 level in ovarian carcinoma overall and by
histological type
Histology Total Positive,(>33 Uml-1)
Adenocarcinomas:
Serous 24 4
Mucinous 8 4
Endometroid 7 4
Undifferentiated 11 2
Clear Cell 5 2
55 16
Table II Sensitivity of CA19-9 relative to tumour
bulk at presentation
Tumour Bulk Total Positive (%)
<2cm 18 4 (18)
2-10cm 13 5(28)
>10cm 24 7 (23)
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Figure 1 Changes in serum CA19-9 level by clinical
course of the disease. Serum CA19-9 was measured
before and at the completion of treatment.
at the conclusion of treatment. This is in marked
contrast to those patients with static or progressive
disease, none of whom showed a similar fall in
CA19-9 serum level.
Overall 40 patients were available for assessment
of response to chemotherapy of whom 23 (58%)
responded. The number of responses by result of
the marker assays is shown in Table III. The
proportion of responders (23%) in the CA19-9+
group was significantly lower than in the CA19-9-
group (74%) (x2=9.34; P<0.01).
Table III Patient response to chemotherapy by presence
or absence of CA125 and CAl9-9
CAJ9-9+ CA19-9- CA125+ CA125-
Responders 3 20 16 7
Failuresa 10 7 15 2
aFailures include patients with both static and
progressive disease.
Comparison of the sensitivities of CA125 and
CA19-9 is shown in Table IV. The overall
sensitivity for CA125 was 76% in this group of
patients, whilst the combined sensitivity, either
CA125 or CAl9-9 positive, rose to 80%.
For monitoring the course of the disease,
variations in CA19-9 levels corresponded to those
in CA125 levels in 8 cases, and reflected the clinical
situation accurately. In three cases the serial
changes in CA19-9 levels provided a better
Table IV Combined sensitivity of CA19-9 and
CA125
Assay Result No. ofpatients (%)
CA19-9-/CA125+ 28 (51)
CA19-9+/CA125- 2 (4)
CA19-9+/CA125+ 14 (25)
CA19-9-/CA125- 11 (20)
correlation with the eventual clinical course of the
disease than changes in CA125 levels. In all three
instances an initial partial response to chemo-
therapy was quickly followed by disease
progression, before treatment was completed.
CA125 levels fell initially, to within the normal
range in two cases, before rising as disease
progressed. However, CA19-9 levels in all three
cases remained static or rose from the start
providing a better indicator of eventual response to
chemotherapy (Figure 2).
In one case an initial normal CA19-9 level rose
during disease progression, whilst CA125 remained
negative throughout.
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Figure 2 Comparison of serial CA19-9 (0) and
CA125 (0) levels in three patients during the course
of chemotherapy. (---) 35 Uml-1.
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When examined immunohistochemically CA19-9
has been shown to occur in association with
ovarian adenocarcinomas (Charpin et al., 1982) the
mucinous histological types reacting much more
frequently than serous types. CA19-9 has been
shown to be secreted into the serum in ovarian
cancer patients (Ricolleau et al., 1983) but results of
serum assays have not previously been reported in
detail. The sensitivity of the CA19-9 assay, 29%, is
not adequate for it to be used alone as a marker
for ovarian tumours. However, a raised CA19-9
level before chemotherapy does appear to be a
significant adverse prognostic factor. This was not
related to the presence of bulk disease, as the
percentage of patients with elevated CA19-9 levels
was independent of the bulk of disease. No such
prognostic significance was apparent for the CA125
antigen in the series.
When the CA19-9 level was elevated there was a
good correlation with the clinical course of the
disease, in those patients in whom serial levels were
measured. In three instances this was more evident
than the serial changes in CA125 level, which fell
initially before rising again as the disease
progressed.
CA125 is the ovarian antigen which has shown
the most clinical promise to date (Bast et al., 1983;
Canney et al., 1984). However, it seems likely that
no tumour associated antigen per se will give useful
information in all patients, not least because
expression is frequently heterogeneous in a given
neoplasm, regardless of the histological appearance
of the cells (Kabawat et al., 1983). However, the
concept of using more than one marker is well
established in the deployment of HCG and AFP to
monitor testicular tumours. The use of a second
marker, could theoretically increase serological
detectability, if the substance were secreted by
additional subpopulations of neoplastic cells. The
efficacy of monitoring response to therapy would
thereby be increased. The "worst case" serial
marker results most accurately reflect the eventual
response in the case of HCG and AFP, and a
similar situation was evident in 4 patients in our
series. Differential secretory activity of cells
expressing CA125 and CA19-9 could explain, at
least in part, the varied changes in serial levels
observed in response to chemotherapy and this
interpretation could be amenable to evaluation by
immunohistochemistry. The present data are
consistent with the view that CA19-9 secretion is
predominantly a property of the more malignant,
or drug resistant, cells within the carcinomas
studied in this series.
The specificity (false positive rate) will be
worsened by using a pair of markers but this is not
relevant once a histological diagnosis has been
made.
Apart from its prognostic significance, measure-
ment of CA19-9 gave additional information to
CA125 in 6 cases (11%), including the two patients
who were CA19-9+ but CA125-, although the sen-
sitivity of CA125, at 76%, was slightly lower in
this particular group of 55 patients than in pre-
viously reported series (Bast et al., 1983; Canney
et al., 1984) and in all patients who have had
CA125 levels measured at this institute where the
overall sensitivity is currently 81/97 (83%). However,
at present no other antigenic marker is as readily
available as an alternative or addition to CA125
and an initial CA19-9 assay could be of some
clinical value.
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